Holen Sie sich die Stockscreener-App
25.67
2.93%
0.73
Handel nachbörslich:
26.00
0.33
+1.29%
Lb Pharmaceuticals Inc Aktie (LBRX) Neueste Nachrichten
LB Pharmaceuticals (NASDAQ:LBRX) Sets New 12-Month HighShould You Buy? - MarketBeat
Bipolar Depression Market Expected to Witness Accelerated Expansion During the Forecast Period (2026-2036) Amid Advancements in Psychiatric Therapies | DelveInsight - The Malaysian Reserve
LB Pharmaceuticals adds neuroscience leader to board, governance - TipRanks
Certain Stock Options of LB Pharmaceuticals Inc are subject to a Lock-Up Agreement Ending on 10-MAR-2026. - marketscreener.com
LB Pharmaceuticals appoints Robert Lenz to board of directors - Investing.com Nigeria
LB Pharmaceuticals appoints Robert Lenz to board of directors By Investing.com - Investing.com Canada
LB Pharmaceuticals Appoints R&D Biotech Executive Robert Lenz, M.D., Ph.D. to Board of Directors - Bitget
Brain drug developer taps Amgen and Neumora alum for its board - Stock Titan
LB Pharmaceuticals Inc (NASDAQ:LBRX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
LB Pharmaceuticals Inc (LBRX) Dividend News Alerts - DividendInvestor.com
LB Pharmaceuticals Inc’s Lock-Up Period Will Expire on March 10th (NASDAQ:LBRX) - Defense World
LB Pharmaceuticals to Participate in Upcoming March Investor Events - Bitget
Biotech developing schizophrenia therapies lines up March investor pitch - Stock Titan
LBRX SEC FilingsLB Pharmaceuticals 10-K, 10-Q, 8-K Forms - Stock Titan
LB Pharmaceuticals (NASDAQ:LBRX) Sets New 52-Week HighTime to Buy? - MarketBeat
JPMorgan Chase & Co. Buys Shares of 1,032,603 LB Pharmaceuticals Inc $LBRX - MarketBeat
LB Pharmaceuticals Inc's (NASDAQ:LBRX) Lock-Up Period Set To End on March 10th - MarketBeat
LB Pharmaceuticals Inc’s (NASDAQ:LBRX) Lock-Up Period Set To End on March 10th - Defense World
LBRX Technical Analysis & Stock Price Forecast - Intellectia AI
Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments - marketscreener.com
LB Pharmaceuticals Inc (NASDAQ:LBRX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
LB Pharmaceuticals Inc (NASDAQ:LBRX) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Given Average Rating of “Hold” by Analysts - Defense World
LB Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Neuro drug developer LB Pharma seeks $300M+ valuation in U.S. IPO - MSN
LB Pharmaceuticals stock rises on $100M financing - MSN
LB Pharmaceuticals announces $100.0 million private placement - marketscreener.com
LB Pharmaceuticals Announces $100 Million Private Placement Financing - TipRanks
LB Pharmaceuticals Signs Multiple Material Agreements - TradingView
Lb Pharmaceuticals Announces $100.0 Million Private Placement - TradingView
LB Pharmaceuticals Announces $100.0 Million Private Placement - The Manila Times
Sector Update: Health Care - marketscreener.com
LB Pharmaceuticals Advances LB-102 Into Long-Term Phase 3 Safety Study for Schizophrenia - TipRanks
LB Pharmaceuticals initiates phase 2 trial for bipolar depression drug By Investing.com - Investing.com Australia
LB Pharmaceuticals initiates Phase 2 trial of LB-102 - Yahoo Finance
LB Pharmaceuticals (NASDAQ:LBRX) Shares Down 6.4%Time to Sell? - MarketBeat
LB Pharmaceuticals initiates phase 2 trial for bipolar depression drug - Investing.com
LB Pharmaceuticals Initiates Phase 2 ILLUMINATE-1 Trial in - GlobeNewswire
LB Pharmaceuticals Initiates Phase 2 ILLUMINATE-1 Trial in Bipolar Depression, Expanding LB-102 Development Program - Sahm
LB Pharmaceuticals Advances LB-102 Into Phase 3, Setting Up a Key Schizophrenia Catalyst for Investors - TipRanks
LB Pharmaceuticals (NASDAQ:LBRX) Hits New 52-Week HighWhat's Next? - MarketBeat
LB Pharmaceuticals appoints Minako Pazdera as general counsel By Investing.com - Investing.com Nigeria
FDA clears Lexicon’s pilavapadin to advance to Phase 3 trials By Investing.com - Investing.com Nigeria
FDA clears Lexicon’s pilavapadin to advance to Phase 3 trials - Investing.com
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):